ACADIA Pharmaceuticals Quarterly Balance Sheet
NASDAQ: ACADHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
ACADIA Pharmaceuticals financial position
As of Jun 30, 2026, ACADIA Pharmaceuticals reported total assets of $1.74 billion, up 42.2% from a year earlier against total liabilities of $436.3 million. Shareholders' equity stood at $1.31 billion, or 75.0% of assets. The company held $385.0 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 3.39, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
ACADIA Pharmaceuticals balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 384.99M | 282.21M | 177.69M | 258.00M | 253.64M | 217.70M | 319.59M | 155.15M | 177.13M | 204.75M | 188.66M | 98.19M |
| Short-Term Investments | 571.49M | 569.25M | 641.99M | 589.02M | 508.36M | 463.88M | 436.40M | 410.18M | 323.81M | 265.77M | 250.21M | 247.73M |
| Receivables | 150.64M | 135.35M | 121.46M | 115.85M | 107.50M | 105.74M | 98.74M | 98.21M | 103.70M | 94.70M | 98.27M | 92.80M |
| Inventory | 108.67M | 112.29M | 111.37M | 105.98M | 110.53M | 102.97M | 91.69M | 86.74M | 86.07M | 66.64M | 40.45M | 25.40M |
| Total Current Assets | 1.22B | 1.10B | 1.06B | 1.08B | 960.55M | 870.94M | 938.32M | 788.28M | 728.92M | 675.30M | 616.13M | 499.17M |
| Property, Plant & Equipment | 17.11M | 14.65M | 7.51M | 3.71M | 3.55M | 3.50M | 4.21M | 3.99M | 4.14M | 4.37M | 4.61M | 4.88M |
| Intangible Assets | 103.45M | 106.17M | 108.89M | 111.61M | 114.34M | 117.06M | 119.78M | 105.52M | 107.86M | 110.20M | 65.49M | 66.86M |
| Total Assets | 1.74B | 1.61B | 1.56B | 1.33B | 1.23B | 1.13B | 1.19B | 976.87M | 914.10M | 855.10M | 748.96M | 632.54M |
| Accounts Payable | 44.57M | 12.25M | 10.90M | 21.75M | 20.10M | 18.09M | 16.19M | 19.08M | 19.88M | 19.33M | 17.54M | 12.31M |
| Total Current Liabilities | 361.44M | 305.52M | 277.11M | 356.58M | 330.02M | 302.53M | 394.87M | 343.94M | 337.85M | 330.60M | 254.25M | 209.60M |
| Total Liabilities | 436.29M | 357.16M | 336.81M | 413.50M | 403.17M | 367.13M | 454.96M | 399.69M | 397.40M | 391.06M | 317.20M | 270.37M |
| Shareholders' Equity | 1.31B | 1.25B | 1.23B | 917.27M | 822.38M | 765.24M | 732.79M | 577.18M | 516.70M | 464.04M | 431.75M | 362.17M |
| Retained Earnings | -1.78B | -1.81B | -1.81B | -2.09B | -2.16B | -2.19B | -2.20B | -2.35B | -2.38B | -2.41B | -2.43B | -2.48B |
| Net Cash (Debt) | 956.47M | 851.46M | 819.69M | 847.02M | 762.00M | 681.58M | 755.99M | 565.33M | 500.94M | 470.52M | 438.87M | 345.92M |
| Shares Outstanding | 172.13M | 171.09M | 170.31M | 169.15M | 168.61M | 167.12M | 166.71M | 166.35M | 165.85M | 164.96M | 164.65M | 163.97M |
This table shows 12 quarterly periods of ACADIA Pharmaceuticals's balance sheet, from Q2 2026 back to Q3 2023, across 17 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow ACAD's reporting calendar. What is a balance sheet?